# Merck & Co.

> Colosso pharma USA con Lead Director che e' anche Lead Director Morgan Stanley e membro CFR, board include CEO Northrop Grumman (defense-pharma crosslink)

## Executive Summary

| Metrica | Valore |
|---------|--------|
| **Fondazione** | 1891 |
| **Sede** | Rahway, NJ, USA |
| **Tipo** | Company (Pharma) |
| **CEO/Chairman** | Robert Davis |
| **Lead Director** | Thomas Glocer |
| **Revenue 2024** | $64.2B |
| **Dipendenti** | ~74,000 |
| **Status** | Active |

---

## Glossario

| Termine | Definizione |
|---------|-------------|
| **MSD** | Merck Sharp & Dohme (nome fuori USA) |
| **Keytruda** | Pembrolizumab, blockbuster oncologico |
| **Gardasil** | Vaccino HPV |
| **Lead Director** | Indipendente che guida board vs Chairman |

---

## Fondazione e Storia

| Dato | Dettaglio |
|------|-----------|
| **Fondazione** | 1891 (spin-off da Merck KGaA tedesca) |
| **Fondatore** | George Merck (emigrato dalla Germania) |
| **Separazione** | 1917 (WWI, confisca asset tedeschi) |
| **Nome fuori USA** | MSD (Merck Sharp & Dohme) |

### Timeline Storica

| Anno | Evento |
|------|--------|
| **1891** | Fondazione come sussidiaria Merck KGaA |
| **1917** | Confisca WWI, diventa azienda USA indipendente |
| **1953** | Merger con Sharp & Dohme |
| **2009** | Acquisizione Schering-Plough ($41B) |
| **2014** | Keytruda approvato FDA |
| **2021** | Robert Davis CEO |
| **2022** | Robert Davis Chairman |
| **2024** | Revenue $64.2B (Keytruda $25B+) |

---

## Governance

### Leadership Attuale

| Ruolo | Nome | Dal |
|-------|------|-----|
| CEO & Chairman | [Robert Davis](../persons/robert-davis.md) | 2021/2022 |
| Lead Director | [Thomas Glocer](../persons/thomas-glocer.md) | 2007 |

### Board of Directors

| Nome | Background |
|------|------------|
| Robert Davis | CEO/Chairman |
| **Thomas Glocer** | **Lead Director, CFR, Morgan Stanley Lead Director** |
| **Kathy Warden** | **CEO Northrop Grumman** |
| Patricia Russo | Ex-Alcatel-Lucent CEO |
| Inge Thulin | Ex-3M CEO |

---

## Thomas Glocer: Il Connettore

### Background

| Dato | Dettaglio |
|------|-----------|
| **Nato** | 8 ottobre 1959, USA |
| **Educazione** | Yale Law School |
| **Carriera principale** | Reuters/Thomson Reuters CEO |

### Ruoli Multipli

| Organizzazione | Ruolo |
|----------------|-------|
| **Merck** | Lead Director (dal 2007) |
| **Morgan Stanley** | Lead Director (dal 2017) |
| **[CFR](../think-tank/cfr.md)** | **Member** |
| Reuters/Thomson Reuters | CEO (2001-2012) |
| BlueVoyant | Executive Chairman (cybersecurity) |
| Cleveland Clinic | Trustee |

### Pattern: Double Lead Director

```
THOMAS GLOCER
    |
    +-- MERCK (Lead Director)
    |       |
    |       +-- $64B pharma
    |
    +-- MORGAN STANLEY (Lead Director)
    |       |
    |       +-- $177B revenue bank
    |
    +-- CFR (Member)
            |
            +-- Foreign policy establishment
```

**Implicazione**: Glocer collega direttamente Big Pharma (Merck) con Wall Street (Morgan Stanley) e foreign policy establishment (CFR).

---

## Kathy Warden: Defense-Pharma Crosslink

### Background

| Dato | Dettaglio |
|------|-----------|
| **Ruolo** | CEO & Chairman Northrop Grumman |
| **Northrop** | 5° contractor difesa USA |
| **Revenue NG** | $41B (2024) |
| **In Merck board** | Dal 2020 |

### Pattern: Defense → Pharma Board

```
KATHY WARDEN
    |
    +-- NORTHROP GRUMMAN (CEO)
    |       |
    |       +-- Defense contractor
    |       +-- $41B revenue
    |       +-- Nuclear systems, drones, cyber
    |
    +-- MERCK (Board)
            |
            +-- $64B pharma
            +-- Vaccines, oncology
```

**Implicazione**: CEO del 5° contractor difesa USA siede nel board del 4° pharma USA. Defense-pharma integration.

---

## Prodotti Principali

| Prodotto | Indicazione | Revenue 2024 |
|----------|-------------|--------------|
| **Keytruda** | Oncologia (PD-1) | $25B+ |
| Gardasil | Vaccino HPV | $9B+ |
| Lagevrio | COVID antivirale | Declining |
| Bridion | Anestesia | $1.5B+ |

### Keytruda: Il Blockbuster

| Metrica | Valore |
|---------|--------|
| **Approvazione** | 2014 |
| **Indicazioni** | 40+ tipi cancro |
| **Revenue 2024** | $25B+ |
| **% revenue Merck** | ~40% |
| **Patent expiry** | 2028 |

---

## Connessioni PowerLink

### Organizzazioni Correlate

| Organizzazione | Tipo Relazione |
|----------------|----------------|
| [CFR](../think-tank/cfr.md) | Glocer member |
| [Morgan Stanley](../bank/morgan-stanley.md) | Glocer Lead Director |
| Northrop Grumman | Warden CEO, board crossover |

### Figure Chiave

| Persona | Ruolo |
|---------|-------|
| [Robert Davis](../persons/robert-davis.md) | CEO/Chairman |
| [Thomas Glocer](../persons/thomas-glocer.md) | Lead Director, CFR |
| [Kathy Warden](../persons/kathy-warden.md) | Board, Northrop CEO |

### Confronto Board Connections

| Pharma | Forum Connection | Finance Connection |
|--------|------------------|-------------------|
| **Merck** | Glocer → CFR | Glocer → Morgan Stanley |
| Moderna | Rubenstein → CFR (Chair) | Rubenstein → Carlyle |
| Pfizer | Gottlieb → AEI | - |
| Roche | Hoffmann → WEF (Co-Chair) | Hoffmann family |

---

## Pattern Identificati

### 1. CFR-Wall Street-Pharma Triangle

Glocer siede simultaneamente:
- Lead Director Merck (pharma)
- Lead Director Morgan Stanley (finance)
- Member CFR (foreign policy)

Collegamento diretto tra i tre mondi.

### 2. Defense-Pharma Integration

Kathy Warden (Northrop Grumman CEO) in Merck board. Pattern di crossover tra complesso militare-industriale e Big Pharma.

### 3. Lead Director Power

Non CEO, non Chairman - ma Lead Director. Ruolo meno visibile ma influente: guida i director indipendenti, ha accesso privilegiato.

### 4. Media-Finance-Pharma

Glocer ex-CEO Reuters (media) → Lead Director Morgan Stanley (finance) + Merck (pharma). Concentrazione di potere cross-settoriale.

---

## Critiche

| Tema | Dettaglio |
|------|-----------|
| **Keytruda pricing** | $150,000+/anno per paziente |
| **Patent games** | Estensioni brevetti aggressive |
| **Vioxx legacy** | $4.85B settlement (2007) |
| **Defense crossover** | Warden solleva conflict of interest |

---

## Fonti

### Ufficiali
- [Merck Official](https://www.merck.com/)
- [Merck Leadership](https://www.merck.com/company-overview/leadership/)
- [Merck Board](https://www.merck.com/company-overview/leadership/board-of-directors/)

### Wikipedia
- [Wikipedia - Merck & Co.](https://en.wikipedia.org/wiki/Merck_%26_Co.)
- [Wikipedia - Tom Glocer](https://en.wikipedia.org/wiki/Tom_Glocer)
- [Wikipedia - Kathy Warden](https://en.wikipedia.org/wiki/Kathy_Warden)

### CFR
- [CFR - Kathy Warden Speaker Series](https://www.cfr.org/event/ceo-speaker-series-kathy-warden-northrop-grumman)

---

*Ultimo aggiornamento: Dicembre 2025*
